|Application ||WB, E|
|Calculated MW||12249 Da|
|Antigen Region||8-35 aa|
|Other Names||ATPase inhibitor, mitochondrial, Inhibitor of F(1)F(o)-ATPase, IF(1), IF1, ATPIF1, ATPI|
|Target/Specificity||This ATPIF1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 8-35 amino acids from the N-terminal region of human ATPIF1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||ATPIF1 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Endogenous F(1)F(o)-ATPase inhibitor limiting ATP depletion when the mitochondrial membrane potential falls below a threshold and the F(1)F(o)-ATP synthase starts hydrolyzing ATP to pump protons out of the mitochondrial matrix. Required to avoid the consumption of cellular ATP when the F(1)F(o)-ATP synthase enzyme acts as an ATP hydrolase. Indirectly acts as a regulator of heme synthesis in erythroid tissues: regulates heme synthesis by modulating the mitochondrial pH and redox potential, allowing FECH to efficiently catalyze the incorporation of iron into protoporphyrin IX to produce heme.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a mitochondrial ATPase inhibitor. Alternative splicing occurs at this locus and three transcript variants encoding distinct isoforms have been identified. [provided by RefSeq].
Sanchez-Cenizo, L., et al. J. Biol. Chem. 285(33):25308-25313(2010)
Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :
Li, N., et al. Int. J. Neurosci. 120(3):217-221(2010)
Contessi, S., et al. J. Bioenerg. Biomembr. 39(4):291-300(2007)
Ma, J., et al. Atherosclerosis 191(1):63-72(2007)
If you have any additional inquiries please email technical services at email@example.com.